European generics firms, squeezed between innovators and payers, seek diversity
This article was originally published in Scrip
Mixed sentiments about the future of the European generic medicines sector were in evidence at the annual meeting of the European Generic medicines Association in Lisbon last week. Upbeat forecasts from industry figures contrasted with a more downbeat assessment from some consultancy firms in the face of the innovation slowdown, competition from R&D firms and the challenges posed by the biosimilars market.
You may also be interested in...
Efforts are under way in the UK on many fronts to develop new treatments and vaccines for coronavirus infection, including researching new uses of existing products and clinical trials of new vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
AMD patients in the UK can legitimately be given compounded bevacizumab (Roche’s Avastin) after the appeals court said NHS trusts could offer a drug off-label for economic reasons where there were no safety or efficacy concerns.